Ignite Creation Date:
2025-12-24 @ 5:13 PM
Ignite Modification Date:
2026-02-11 @ 6:29 AM
Study NCT ID:
NCT04585750
Status:
RECRUITING
Last Update Posted:
2025-10-31
First Post:
2020-10-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Sponsor:
PMV Pharmaceuticals, Inc
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Solid Tumor | View |
| None | Advanced Malignant Neoplasm | View |
| None | Metastatic Cancer | View |
| None | Metastatic Solid Tumor | View |
| None | Lung Cancer | View |
| None | Ovarian Cancer | View |
| None | Endometrial Cancer | View |
| None | Prostate Cancer | View |
| None | Colorectal Cancer | View |
| None | Breast Cancer | View |
| None | Other Cancer | View |
| None | Locally Advanced | View |
| None | Head and Neck Cancer | View |
| None | Gall Bladder Cancer | View |
| None | Small Cell Lung Cancer | View |
| None | Small Cell Lung Cancer ( SCLC ) | View |
| None | Small Cell Lung Carcinoma | View |
| None | NSCLC | View |
| None | NSCLC (Non-small Cell Lung Cancer) | View |
| None | SCLC | View |
| None | Non-Small Cell Lung Carcinoma | View |
| None | Triple Negative Breast Cancer | View |
| None | TNBC | View |
| None | HER2+ Breast Cancer | View |
| None | Non-Small Cell Lung Cancer | View |
| None | ER/PR Positive Breast Cancer | View |
| None | HER2- Breast Cancer | View |
| None | HER2-positive Breast Cancer | View |
| None | HER2-negative Breast Cancer | View |
| None | ER/PR(+), Her2(-) Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | PC14586 | View |
| None | p53 | View |
| None | Y220C | View |
| None | Phase 1 | View |
| None | Phase 1/2 | View |
| None | PMV | View |
| None | PMV Pharma | View |
| None | p53 mutation | View |
| None | TP53 | View |
| None | TP53 mutation | View |
| None | p53 mutant | View |
| None | p53 reactivator | View |
| None | pembrolizumab | View |
| None | Keytruda | View |
| None | combination | View |
| None | PD-1 | View |
| None | PD-L1 | View |
| None | anti-PD-1 | View |
| None | Merck | View |
| None | MSD | View |
| None | IgG4 | View |
| None | mAb | View |
| None | Phase 1b | View |
| None | NGS | View |
| None | Next Generation Sequencing | View |
| None | precision | View |
| None | Phase 2 | View |
| None | Rezatapopt | View |